BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee EW, Alanis L, Cho SK, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol. 2016;17:472-488. [PMID: 27390539 DOI: 10.3348/kjr.2016.17.4.472] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Cournane S, Mccavana J, Manley M, Gray L, Mccann J, Lucey J. Yttrium-90 selective internal radiation therapy, examining dose rates and radiation protection precautions. Physica Medica 2019;65:121-7. [DOI: 10.1016/j.ejmp.2019.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Reguera-Berenguer L, Orcajo-Rincón J, Rotger-Regí A, Matilla-Peña AM, Echenagusia-Boyra M, Pérez-Pascual R, Marí-Hualde A, Alonso-Farto JC. Downstaging of bilobar hepatocellular carcinoma after radioembolization with 90Y microspheres as a bridge to liver transplantation. Rev Esp Med Nucl Imagen Mol 2017;36:329-32. [PMID: 28268101 DOI: 10.1016/j.remn.2016.12.006] [Reference Citation Analysis]
3 Reimer P, Virarkar MK, Binnenhei M, Justinger M, Schön MR, Tatsch K. Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients. Cardiovasc Intervent Radiol 2018;41:744-52. [DOI: 10.1007/s00270-017-1871-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
4 Hsu CY, Wang CW, Cheng AL, Kuo SH. Hypofractionated particle beam therapy for hepatocellular carcinoma–a brief review of clinical effectiveness. World J Gastrointest Oncol 2019; 11(8): 579-588 [PMID: 31435460 DOI: 10.4251/wjgo.v11.i8.579] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017;67:173-83. [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
6 Lee WW; K-SPECT Group. Clinical Applications of Technetium-99m Quantitative Single-Photon Emission Computed Tomography/Computed Tomography. Nucl Med Mol Imaging 2019;53:172-81. [PMID: 31231437 DOI: 10.1007/s13139-019-00588-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
7 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology 2018;129:112-22. [DOI: 10.1016/j.radonc.2017.11.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
8 Spina JC, Hume I, Pelaez A, Peralta O, Quadrelli M, Garcia Monaco R. Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors. Radiographics 2019;39:578-95. [PMID: 30844345 DOI: 10.1148/rg.2019180095] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
9 Zheng Z, Pan X, Xu J, Wu Z, Zhang Y, Wang K. Advances in tracking of polysaccharides in vivo: Labeling strategies, potential factors and applications based on pharmacokinetic characteristics. International Journal of Biological Macromolecules 2020;163:1403-20. [DOI: 10.1016/j.ijbiomac.2020.07.210] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Zheng J, Irani Z, Lawrence D, Flaherty K, Arellano RS. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series. Journal of Vascular and Interventional Radiology 2018;29:1369-75. [DOI: 10.1016/j.jvir.2018.04.030] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
11 Law M, Wong KK, Tso WK, Lee V, Luk MY, Tong CC, Chu F. Personnel dose reduction in 90Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward. Br J Radiol 2017;90:20160591. [PMID: 27993095 DOI: 10.1259/bjr.20160591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Joo I, Kim HC, Kim GM, Paeng JC. Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know. Korean J Radiol 2018;19:209-22. [PMID: 29520178 DOI: 10.3348/kjr.2018.19.2.209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
13 Kostelnik TI, Orvig C. Radioactive Main Group and Rare Earth Metals for Imaging and Therapy. Chem Rev 2019;119:902-56. [PMID: 30379537 DOI: 10.1021/acs.chemrev.8b00294] [Cited by in Crossref: 123] [Cited by in F6Publishing: 84] [Article Influence: 30.8] [Reference Citation Analysis]
14 Kim JH, Shim JH, Yoon HK, Ko HK, Kim JW, Gwon DI. Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein. Liver Int 2018;38:1646-54. [PMID: 29436101 DOI: 10.1111/liv.13719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
15 Kim PH, Choi SH, Kim JH, Park SH. Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy. Korean J Radiol. 2019;20:385-398. [PMID: 30799569 DOI: 10.3348/kjr.2018.0496] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
16 Zheng L, Li HL, Guo CY, Luo SX. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas. Korean J Radiol 2018;19:237-46. [PMID: 29520181 DOI: 10.3348/kjr.2018.19.2.237] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
17 Caine M, Carugo D, Zhang X, Hill M, Dreher MR, Lewis AL. Review of the Development of Methods for Characterization of Microspheres for Use in Embolotherapy: Translating Bench to Cathlab. Adv Healthcare Mater 2017;6:1601291. [DOI: 10.1002/adhm.201601291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
18 Sun JY, Yin T, Zhang XY, Lu XJ. Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol 2019;234:12116-21. [PMID: 30648254 DOI: 10.1002/jcp.28019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
19 Reguera-berenguer L, Orcajo-rincón J, Rotger-regí A, Matilla-peña A, Echenagusia-boyra M, Pérez-pascual R, Marí-hualde A, Alonso-farto J. Downstaging of bilobar hepatocellular carcinoma after radioembolization with 90 Y microspheres as a bridge to liver transplantation. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2017;36:329-32. [DOI: 10.1016/j.remnie.2017.06.005] [Reference Citation Analysis]
20 Nakamura M. Organosilica Nanoparticles and Medical Imaging. Enzymes 2018;44:137-73. [PMID: 30360813 DOI: 10.1016/bs.enz.2018.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Kim JH, Shim JH, Lee HC, Sung KB, Ko HK, Ko GY, Gwon DI, Kim JW, Lim YS, Park SH. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int. 2017;37:1861-1868. [PMID: 28581250 DOI: 10.1111/liv.13487] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
22 Pérez-López A, Martín-Sabroso C, Torres-Suárez AI, Aparicio-Blanco J. Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom. Pharmaceutics 2020;12:E1028. [PMID: 33126622 DOI: 10.3390/pharmaceutics12111028] [Reference Citation Analysis]
23 Bakker RC, de Roos R, Ververs FFT, Lam MGEH, van der Lee MK, Zonnenberg BA, Krijger GC. Blood and urine analyses after radioembolization of liver malignancies with [166Ho]Ho-acetylacetonate-poly(l-lactic acid) microspheres. Nucl Med Biol 2019;71:11-8. [PMID: 31108463 DOI: 10.1016/j.nucmedbio.2019.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Li Q, Liu XP, Wang DW, Shen YM, Jia Q, Liu WT. Brachytherapy using elastin-like polypeptide with different concentrations of 131I for treatment of VX2 liver tumor in rabbits. Shijie Huaren Xiaohua Zazhi 2019; 27(8): 485-493 [DOI: 10.11569/wcjd.v27.i8.485] [Reference Citation Analysis]